Page 9 - Mapa infectii 2025

P. 9

Protec ie împotriva gripei

pe parcursul întregului sezon

CHIAR SUB NASUL TĂU

Fluenz - singurul vaccin gripal cu administrare intranazală,
asigură protec ia copiilor și adolescen ilor cu vârsta cuprinsă
între 24 de luni și mai pu in de 18 ani împotriva gripei.

Fluenz asigură protec ie Fluenz este singurul vaccin
împotriva gripei timp de gripal intranazal care asigură
până la 12 luni. 3 un răspuns imun pe 3 căi. 1,4-7

Fluenz poate reduce spitalizările Modul de administrare Fluenz
copiilor din cauza tuturor reușește să crească ratele de
tulpinilor de gripă cu până la vaccinare conform autorită ilor
63% comparativ cu IIV.* 8-11 de sănătate, ﬁind preferat de
părin i. 2,4,12-18

*IIV - inactivated inﬂuenza vaccine - vaccin gripal cu virus inactivat
Referin e: 1. Fluenz Trivalent, suspensie de spray nazal pentru vaccin gripal (virus viu atenuat, administrare nazală). Rezumatul caracteristicilor produsului. AstraZeneca UK Limited; 2. UK Health Security Agency.
Chapter 19: Inﬂuenza. In: Ramsay M, ed. Immunisation against infectious disease. Department of Health and Social Care, National Health Service. Updated November 10, 2023. Accessed October 2, 2024.
https://assets.publishing.service.gov.uk/media/654cf306014cc90010677371/Green-book-chapter-19-inﬂuenza-_3November2023.pdf; 3. Ambrose CS, Yi T, Walker RE, Connor EM. Duration of protection provided
by live attenuated inﬂuenza vaccine in children. Pediatr Infect Dis J. 2008;27(8):744-748. doi:10.1097/INF.0b013e318174e0f8; 4. Hoft DF, Babusis E, Worku S, et al. Live and inactivated inﬂuenza vaccines induce
similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis. 2011;204(6):845-853. doi:10.1093/infdis/jir43; 5. Beyer WEP, Palache AM, de Jong JC, Osterhaus
ADME. Coldadapted live inﬂuenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efﬁcacy: a meta-analysis. Vaccine. 2002;20(9-10):1340-1353.
doi:10.1016/s0264-410x(01)00471-6; 6. Mohn KGI, Smith I, Sjursen H, Cox RJ. Immune responses after live attenuated inﬂuenza vaccination. Hum Vaccin lmmunother. 2018;14(3):571-578.
doi:10.1080/21645515.2017.1377376; 7. Cox RJ, Brokstad KA, Ogra P. Inﬂuenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated inﬂuenza
vaccines. Scand J lmmunol. 2004;59(1):1-15. doi:10.1111/j.0300-9475.2004.01382.x; 8. National Services Scotland. Flu vaccine effectiveness in Scottish primary school age children from the 2015/16 season.
Health Protection Scotland. 2016. Accessed October 2, 2024. https://webarchive.nrscotland.gov.uk/20190221073445/https://www.hps.scot.nhs.uk/resourcedocument.aspx?id= 5529; 9. Boddington NL,
Warburton F, Zhao H, et al. Inﬂuenza vaccine effectiveness against hospitalisation due to laboratory-conﬁrmed inﬂuenza in children in England in the 2015-2016 inﬂuenza season—a testnegative case-control
study. Epidemiol Infect. 2019;147:e201. doi:10.1017/S0950268819000876; 10. Boddington NL, Mangtani P, Zhao H, et al. Live-attenuated inﬂuenza vaccine effectiveness against hospitalization in children aged
2-6 years, the ﬁrst three seasons of the childhood inﬂuenza vaccination program in England, 2013/14-2015/16. Inﬂuenza Other Respir Viruses. 2022;16(5):897-905. doi:10.1111/irv.12990; 11. Pebody RG, Zhao H,
Whitaker HJ, et al. Effectiveness of inﬂuenza vaccine in children in preventing inﬂuenza associated hospitalisation, 2018/19, England. Vaccine. 2020;38(2):158-164. doi:10.1016/j.vaccine.2019.10.035; 12. Nohynek
H, Baum U, Jaaskelainen N, Ikonen N, Sundman J. Seasonal inﬂuenza vaccine coverage, especially live attenuated vaccine coverage, increases steadily among children in Finland according to a nationwide
register-based cohort study. Paper presented at: 2019 ESPID annual meeting; May 6-May 11, 2019; Ljubljana, Slovenia; 13. Seasonal inﬂuenza vaccination coverage: season 2023-2024, children aged 2 years, all
inﬂuenza vaccines. Finnish Institute for Health and Welfare. Updated September 2, 2024. Accessed October 2, 2024. https://www.thl.ﬁ/roko/vaccreg/atlas/public/atlas-en.html?show=inﬂuenza; 14. Seasonal
inﬂuenza vaccination coverage:season 2023-2024, children aged 3-6 years, all inﬂuenza vaccines. Finnish Institute for Health and Welfare. Updated September 2, 2024. Accessed October 2, 2024.
https://www.thl.ﬁ/roko/vaccreg/atlas/public/atlas-en.html?show=inﬂuenza; 15. National Institute for Health and Care Excellence. Vaccine uptake in the general population. Interventions to increase vaccine uptake
by targeting acceptability. Department of Health and Social Care, National Health Service. 2022. Accessed October 2, 2024. https://www.nice.org.uk/guidance/ng218; 16. Children’s ﬂu vaccine. Department of
Health and Social Care, National Health Service. Updated December 13, 2023. Accessed October 2, 2024. https://www.nhs.uk/conditions/vaccinations/child-ﬂu-vaccine; 17. Public Health England. Extension of
the inﬂuenza immunisation programme to children in England: experiences of using live attenuated inﬂuenza vaccine (LAIV) in school age children 2013-16. Department of Health and Social Care, National Health
Service. 2016. Accessed October 2, 2024.https://assets.publishing.service.gov.uk/media/5c2f4ce1e5274a65cc0f5d69/Extension_of_the_Inﬂuenza_immunisation_programme_to_children_in_England.pdf; 18.
Harris C, Cottrell S, Perry M, etal. A pilot intervention to improve uptake and equality of childhood inﬂuenza vaccination in an area of Wales, through the introduction of a mixed delivery model including nursery
school immunisation sessions. Vaccine. 2023;41(18):2990-2995. doi:10.1016/j.vaccine.2023.03.075.
Acest material este destinat profesioniștilor din domeniul sănătăţii
Medicament eliberat pe bază de prescrip ie medicală.
Evenimentele adverse pot ﬁ raportate online https://contactazmedical.astrazeneca.com, sau la adresa farmacovigilenta@astrazeneca.com
Primi i acest material în urma acordului dvs. de a primi comunicări de la AstraZeneca Pharma SRL.
Dacă nu mai dori i să primi i mesaje de la noi, vă rugăm să vă dezabona i AICI.
Mai multe informa ii privind modul în care AstraZeneca prelucrează datele dvs. cu caracter personal, care sunt drepturile dvs. și cum le pute i
exercita sunt disponibile în Nota de Informare privind prelucrarea datelor cu caracter personal disponibilă AICI.
RO-26279/06.2025

Pentru informa ii suplimentare, vă rugăm să
consulta i versiunea actualizată a Rezumatului ASTRAZENECA PHARMA S.R.L.
Caracteristicilor Produsului, scanând codul QR Str. Tipograﬁlor 1A, MUSE Ofﬁces, Et. 2 si 3, 013714, sector 1,
București, Tel.: +40 21 317 60 41;
Email: ofﬁce.romania@astrazeneca.com

4 5 6 7 8 9 10 11 12 13 14